FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter: FRONTEO) is a national research and development agency, the National Institute of Biomedical Innovation, Health and Nutrition (Location: Ibaraki City, Osaka Prefecture, President: Yusuke Nakamura. , hereinafter: NIBIOHN), we are pleased to announce that the medical paper search AI “Amanogawa” has been introduced.

　Amanogawa is a paper search AI system that uses FRONTEO's unique natural language processing AI technology.When you enter words, sentences, hypotheses, etc. that you want to look up, AI instantly detects related papers from the data of more than 3000 million papers posted on PubMed*. The use of AI has greatly streamlined the search and analysis of research papers, which used to take a huge amount of time by humans.In addition, the time required to collect and verify the information required to generate hypotheses is dramatically reduced and the accuracy is improved. In addition, it is possible to find information that could not be found by conventional keyword searches and information that is not biased by the searcher, realizing objective and comprehensive analysis in medical and drug discovery research.

　Amanogawa will be used in NIBIOHN's drug discovery resource research project.Upon introduction, we received the following comments from the person in charge of the project.

　“When I used Amanogawa to formulate a research strategy, I found it interesting because it found many papers that would not have been found in a standard keyword search, and included several interesting papers. I expect that Amanogawa will greatly contribute to groundbreaking technological development and efficient research promotion."

"Amanogawa" application screen example. Each point of "Space Map" shows a treatise

　FRONTEO will contribute to improving the quality of medical care and the QOL of patients by utilizing in-house developed AI, which has strengths in natural language processing, and supporting the efficiency and success rate of drug discovery research and business.

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

*Biomedical article database created by the National Center for Biological Science Information in the U.S. National Library of Medicine

■About NIBIOHN　URL:https://www.nibiohn.go.jp/
Established on April 2015, 1 through the merger of the National Institute of Biomedical Innovation and the National Institute of Health and Nutrition.It is characterized by a wide range of research from medical to health science, and aims to ensure the maximum results of research and development in order to contribute to the sound development of the national economy and other public interests by improving the level of science and technology in Japan. It is positioned as a national research and development agency.
Twitter URL: https://twitter.com/NIBIOHN
Instagram URL: https://www.instagram.com/p/CnBkuotSIAZ/

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

※FRONTEO, Amanogawa, KIBIT, conceptencoder, Looca Cross are registered trademarks of FRONTEO.